Celcuity (CELC) Competitors $50.29 -2.13 (-4.06%) As of 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CELC vs. GH, RDNT, OPCH, SHC, BTSG, WGS, CON, SGRY, PRVA, and HTFLShould you be buying Celcuity stock or one of its competitors? The main competitors of Celcuity include Guardant Health (GH), RadNet (RDNT), Option Care Health (OPCH), Sotera Health (SHC), BrightSpring Health Services (BTSG), GeneDx (WGS), Concentra Group Holdings Parent (CON), Surgery Partners (SGRY), Privia Health Group (PRVA), and Heartflow (HTFL). These companies are all part of the "healthcare" industry. Celcuity vs. Its Competitors Guardant Health RadNet Option Care Health Sotera Health BrightSpring Health Services GeneDx Concentra Group Holdings Parent Surgery Partners Privia Health Group Heartflow Celcuity (NASDAQ:CELC) and Guardant Health (NASDAQ:GH) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership. Do institutionals & insiders hold more shares of CELC or GH? 63.3% of Celcuity shares are held by institutional investors. Comparatively, 92.6% of Guardant Health shares are held by institutional investors. 15.8% of Celcuity shares are held by company insiders. Comparatively, 6.1% of Guardant Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is CELC or GH more profitable? Celcuity has a net margin of 0.00% compared to Guardant Health's net margin of -49.93%. Guardant Health's return on equity of 0.00% beat Celcuity's return on equity.Company Net Margins Return on Equity Return on Assets CelcuityN/A -150.07% -64.67% Guardant Health -49.93%N/A -28.95% Do analysts recommend CELC or GH? Celcuity presently has a consensus price target of $50.60, indicating a potential upside of 0.62%. Guardant Health has a consensus price target of $57.50, indicating a potential downside of 6.92%. Given Celcuity's higher possible upside, research analysts clearly believe Celcuity is more favorable than Guardant Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celcuity 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Guardant Health 0 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 1 Strong Buy rating(s) 3.06 Which has more volatility and risk, CELC or GH? Celcuity has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Guardant Health has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Which has stronger earnings & valuation, CELC or GH? Celcuity has higher earnings, but lower revenue than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelcuityN/AN/A-$111.78M-$3.45-14.58Guardant Health$739.02M10.42-$436.37M-$3.35-18.44 Does the media refer more to CELC or GH? In the previous week, Guardant Health had 11 more articles in the media than Celcuity. MarketBeat recorded 13 mentions for Guardant Health and 2 mentions for Celcuity. Guardant Health's average media sentiment score of 1.25 beat Celcuity's score of 0.30 indicating that Guardant Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Guardant Health 11 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGuardant Health beats Celcuity on 11 of the 16 factors compared between the two stocks. Get Celcuity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CELC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELC vs. The Competition Export to ExcelMetricCelcuityMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.14B$3.06B$5.76B$9.75BDividend YieldN/A2.24%4.40%4.10%P/E Ratio-14.6221.0030.8325.91Price / SalesN/A392.25469.77121.46Price / CashN/A43.2325.7828.79Price / Book16.179.739.466.03Net Income-$111.78M-$54.08M$3.27B$265.29M7 Day Performance-2.48%3.12%2.37%2.86%1 Month Performance265.21%4.57%3.88%1.23%1 Year Performance189.86%10.22%30.52%19.11% Celcuity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELCCelcuity1.0102 of 5 stars$50.29-4.1%$50.60+0.6%+202.1%$2.14BN/A-14.6240GHGuardant Health3.3401 of 5 stars$59.47+1.0%$57.50-3.3%+111.6%$7.34B$739.02M-17.752,021Positive NewsRDNTRadNet3.2716 of 5 stars$66.29-1.7%$71.60+8.0%+7.8%$5.19B$1.83B-331.4311,021Positive NewsOPCHOption Care Health4.8163 of 5 stars$28.19-0.5%$35.75+26.8%-9.7%$4.60B$5.00B22.558,088Positive NewsSHCSotera Health1.3718 of 5 stars$15.80+0.4%$16.00+1.3%+6.5%$4.47B$1.10B197.523,000Positive NewsBTSGBrightSpring Health Services1.7379 of 5 stars$23.09+2.9%$25.67+11.2%+97.9%$3.98B$11.27B74.4935,000News CoveragePositive NewsWGSGeneDx2.1771 of 5 stars$125.90-0.4%$101.63-19.3%+259.8%$3.63B$305.45M2,518.001,200Positive NewsInsider TradeCONConcentra Group Holdings Parent2.2839 of 5 stars$22.85-1.7%$27.50+20.4%+1.0%$2.98B$1.90B19.2011,250Positive NewsSGRYSurgery Partners2.9968 of 5 stars$22.49-1.4%$33.00+46.7%-29.8%$2.92B$3.24B-15.7315,000News CoveragePRVAPrivia Health Group4.2344 of 5 stars$21.37+0.5%$28.00+31.0%+5.4%$2.61B$1.74B194.291,140News CoveragePositive NewsHTFLHeartflowN/A$29.97-3.8%N/AN/A$2.53BN/A0.00699 Related Companies and Tools Related Companies Guardant Health Competitors RadNet Competitors Option Care Health Competitors Sotera Health Competitors BrightSpring Health Services Competitors GeneDx Competitors Concentra Group Holdings Parent Competitors Surgery Partners Competitors Privia Health Group Competitors Heartflow Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CELC) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celcuity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access